FBR Capital Reiterates Outperform on Cerus (CERS) Following FDA Approval

Pre-Open Stock Movers 03/16: (CERS) (ORCL) (RLYP) Higher; (BTU) (CLBS) (SUNE) Lower (more...)

Peabody Energy (NYSE: BTU) 51% LOWER; disclosed the following in its 10-K on Wednesday: As a result of operating losses and negative cash flows from operations and our election to exercise a 30-day grace period with respect to certain interest payments, together with other factors, including the possibility that a covenant default or other event of default could cause certain of our indebtedness to become immediately due and payable (after the expiration of any applicable grace period), we may not have sufficient liquidity to sustain operations and to continue as a... More

Cerus (CERS) Announces FDA Approval of INTERCEPT Blood System

Cerus Corporation (NASDAQ: CERS) announced U.S. Food and Drug Administration (FDA) approval of the INTERCEPT Blood System for treatment of platelets suspended in 100% plasma. This extended label claim further enhances compatibility with commonly used platelet collection methods.

The INTERCEPT Blood System was initially approved by the FDA in... More

Cerus (CERS) Announces Pathogen Reduction Technology Included in FDA’s Revised Guidance Document on Bacterial Safety Standards for Platelets

Cerus Corporation (NASDAQ: CERS) announced that the U.S. Food and Drug Administration (FDA) has issued a revised draft guidance document titled Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion; Draft Guidance for Industry. The document is intended to provide blood centers with recommendations for controlling the risk of bacterial contamination of platelets, and pathogen reduction technology is included as a recommended method to reduce... More